Specifically, DUX4 modulates WNT/β-catenin signaling in FSHD, promotes tumorigenesis via MYC pathways in rhabdomyosarcoma, and influences MYC amplification in CIC-DUX sarcomas while also exhibiting p53-independent toxicity [58,59,60,61]. Here, MYC is linked to sarcoma.